Kirschgesner (2021)
Ulcerative colitis
Gastroenterology • Other Data • US, France
Study Metrics
Covariates
23
PICO Comparisons
0
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Kirschgesner |
| Publication Year: | 2021 |
| DOI: | https://doi.org/10.1002/pds.5356 |
| Preprint: | No preprint |
Institution & Funding
| Institution Type: | Academic |
| Institutions: | Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Hôpital Saint-Antoine |
| Funding: | Declared: Research institute |
| Funding Institutions: | The investigators conducted the research independently through funding from internal sources of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School. |
Study Context
| Disease: | Ulcerative colitis |
| Disease Category: | Gastroenterology |
| Data Type: | Other |
| Number of Data Sources: | 3 |
| Geography: | US, France |
| Eligible Sample: | 22051.0 |
| Number of Treatments: | 2 |
Analytical Methods
| Matching Method: | PS Matching |
| Analysis Method: | Log-binomial regression |
| Estimand: | Not defined |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | UC SUCCESS |
| Registration Number: | NCT00537316 |
| Target Trial DOI: | https://doi.org/10.1053/j.gastro.2013.10.052 |
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: None |
| Funding Source: | Declared: Research institute |
| Funding Institutions: | The investigators conducted the research independently through funding from internal sources of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School. |